AI assistant
Sending…
Syndax Pharmaceuticals Inc — Director's Dealing 2021
Feb 5, 2021
31977_dirs_2021-02-05_4249b0e9-f29d-423a-ae97-c0e4739ce552.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-02-03
Reporting Person: Ordentlich Peter (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-03 | Stock Option (Right to Buy) | $21.36 | A | 80000.00 | Acquired | 2031-02-03 | Common Stock (80000.00) | Direct |
Footnotes
F1: 1/48th of the shares subject to the option shall vest monthly over a four-year period.
More from Syndax Pharmaceuticals Inc
Proxy Solicitation & Information Statement
2026
Jun 4
Capital/Financing Update
2026
Jun 4
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6